Published in Biotech Business Week, April 26th, 2004
The research - conducted by a team of scientists led by George Q. Daley, MD, PhD, of Harvard Medical School and presented at the American Association for Cancer Research annual meeting - shows that AP23464 effectively suppresses even those leukemia cells containing robust and common Gleevec-resistant mutants and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.